A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

Clinical trial NCT03820726 · COMPLETED

Trial details

NCT number: NCT03820726
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Lung Diseases, Interstitial

Start date: 2019-04-16
Primary completion: 2022-08-30
Enrollment: 435

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.